Cite
HARVARD Citation
Mueller, V. et al. (2021). Preservation of quality of life in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial). European journal of cancer. pp. 223-233. [Online].